Multi-Platform
Approach
Addressing Solid Tumors with
Non-Viral T-Cell Therapies and
Cytokine-Driven Technology
Sleeping Beauty
Rapid Non-Viral
Genetic Modification of
TCR-T and CAR-T Cells
Controlled IL-12
Turning
Cold Tumors Hot
by Activating an
Immune Response

Developing non-viral and cytokine-driven cell and gene therapies to effectively
access and treat the millions of people diagnosed globally each year with
solid tumors by weaponizing the body’s immune system.
Leveraging its multi-platform approach,
Ziopharm is at the forefront of immuno-oncology.

Our focus at Ziopharm is to reestablish the immune system and allow the body’s own defenses to destroy tumors.

Sleeping Beauty T-Cell Therapy
Sleeping Beauty is one of the most clinically advanced non-viral cell therapy platforms that genetically modifies T cells to express tumor-targeting receptors, TCR or CAR. This technology enables a new, scalable approach to manufacturing cell therapy products called Rapid Personalized Manufacturing or RPM. It has the potential to produce these therapies in a fraction of the time and cost compared to what’s currently available.
Controlled IL-12
Interleukin 12, or IL-12, is a master regulator of the immune system. Ziopharm uses it to weaponize the immune system and call T cells deep into tumors. With its gene therapy technology, Ziopharm precisely controls expression of IL-12 to ensure the best possible response to treatment. Controlled IL-12 is currently being studied in recurrent glioblastoma and pediatric brain tumors.
Helping patients leverage the power of the immune system in the fight against cancer.